Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 6-Chloronicotinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.55 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.55 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.55 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.55 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.55 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.55 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.55 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.55 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.55 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.55 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.55 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.55 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.55 |
| ▸ | KCNQ3 known ✓ | O43525 | 3/20 | 0.47 |
| ▸ | KCNQ2 known ✓ | O43526 | 3/20 | 0.47 |
| ▸ | KCNQ1 known ✓ | P51787 | 1/20 | 0.47 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Chloronicotinic Acid SCHEMBL104580 | 0.98 | NAPRT (1.00) | NAPRTP4HA1P4HTMMIFGABRP | |
| 6-Chloronicotinic Acid SCHEMBL29524158 | 0.98 | NAPRT (1.00) | NAPRTP4HA1P4HTMMIFGABRP | |
| 6-Chloronicotinic Acid SCHEMBL10575126 | 0.96 | NAPRT (0.96) | NAPRTP4HA1P4HTMMIFGABRP | |
| 6-Chloronicotinic Acid SCHEMBL17541528 | 0.94 | NAPRT (0.92) | NAPRTP4HA1P4HTMMIFGABRP | |
| 6-Chloronicotinic Acid SCHEMBL27649626 | 0.90 | NAPRT (0.85) | NAPRTP4HA1P4HTMMIFGABRP | |
| 6-Chloronicotinic Acid SCHEMBL3975934 | 0.85 | NAPRT (0.76) | NAPRTP4HA1P4HTMMIFGABRP | |
| 6-Chloronicotinic Acid SCHEMBL4044448 | 0.85 | HCAR3 (0.78) | NAPRTHCAR3 | |
| Hydrochloric Acid SCHEMBL2928501 | 0.84 | NAPRT (0.69) | NAPRTL3MBTL1DGAT1RAB9ASMN1; SMN2 | |
| SCHEMBL17801 | 0.82 | NAPRT (0.72) | NAPRTL3MBTL1DGAT1RAB9ASMN1; SMN2 | |
| SCHEMBL29760376 | 0.82 | NAPRT (0.72) | NAPRTL3MBTL1DGAT1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9056376-A | — | — | None | — | — | JP | disclosed |
| US-20210403460-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2021-12-30 | — | — | US | disclosed |
| EP-3492451-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3555079-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | Isocure Biosciences Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10323002-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| EP-3492451-A2 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| WO-2019078040-A1 | COMPOUND, BONDED BODY OF SAME, AND ORGANIC SEMICONDUCTOR MATERIAL | 国立大学法人大阪大学 | 2019-04-25 | — | — | WO | disclosed |
| EP-3216784-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-26 | — | — | EP | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
| JP-H0956376-A | PROMOTION OF PROLIFERATION OF MICROORGANISM | NIPPON NOHYAKU CO LTD | 1997-03-04 | — | — | JP | disclosed |
| US-5455348-A | Anticoagulants | Thomae, Karl (DE) | 1995-10-03 | — | — | US | disclosed |
| US-4882342-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-11-21 | — | — | US | disclosed |
| EP-0330939-A2 | Acrylic acid morpholides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4833250-A | Process of converting a carboxylic acid or carboxylic acid halide group to a trihalomethyl group | ICI AMERICAS INC. (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0281965-A1 | Method of converting a carboxylic acid or carboxylic acid halide group to a trihalomethyl group | ICI AMERICAS INC. (US) | 1988-09-14 | — | — | EP | disclosed |
| US-4139623-A | HYPOTENSIVE AGENTS | C-G CORP. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4027027-A | BETA-RECEPTOR-BLOCKERS, HYPOTENSIVES AND VALODILATORS; FOR TREATING ARRYTHMIAS AND ANGINA PECTORIS | CIBA-GEIGY CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
| JP-H00956376-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403460-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | GABRP 2849/4885GABRD 2653/4885GABRA1 3152/4885 |
| US-10323002-B2 | Process for the preparation of histamine H3 receptor modulators | HRH3, HRH4, HRH1 | GABRP 148/4885GABRD 428/4885GABRA1 121/4885 |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | IDH1, IDH2, IDH3A | GABRP 2849/4885GABRD 2653/4885GABRA1 3152/4885 |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | GABRP 2849/4885GABRD 2653/4885GABRA1 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.